- Home
- BIDU vs TAK Comparison
BIDU vs TAK Comparison
Compare BIDU & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIDU | TAK |
|---|---|---|
| Founded | 2000 | 1781 |
| Country | China | Japan |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BIDU | TAK |
|---|---|---|
| Price | $118.49 | $18.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $153.92 | N/A |
| AVG Volume (30 Days) | 2.0M | ★ 2.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.86% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.47 | $0.04 |
| Revenue Next Year | $6.92 | $0.92 |
| P/E Ratio | $42.45 | ★ $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $74.71 | $12.99 |
| 52 Week High | $165.30 | $18.82 |
Technical Indicators
Market Signals| Indicator | BIDU | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 23.32 | 53.95 |
| Support Level | $83.98 | $14.78 |
| Resistance Level | $120.43 | $18.82 |
| Average True Range (ATR) | 4.20 | 0.23 |
| MACD | -2.24 | -0.11 |
| Stochastic Oscillator | 8.60 | 43.22 |
Price Performance
Historical ComparisonAbout BIDU Baidu Inc. ADS
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 70% of core revenue from online marketing services from its search engine in 2024. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.